DDInter612 DDInter1376
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Duvelisib may lead to a major life threatening interaction when taken with Sonidegib
Duvelisib may lead to a major life threatening interaction when taken with Upadacitinib